Fig. 3.

Work productivity and activity impairment in CD patients. TWPI (a) and activity impairment (b) are shown for the whole observational period. After the onset of IFX therapy, both impairments were statistically significantly improved. For absenteeism (c) as well as presenteeism (d), similar outcomes were reported. e Comparison of TWPI and activity impairment between biological-naïve (white columns) and pre-treated (dark gray columns) patients demonstrating a statistically significant enhancement in both groups for TWPI and activity impairment, respectively, after 3 months of IFX treatment (mean change from BL). The decrease of work incapacity days before BL and after 3 months of IFX therapy is shown in (f) indicated as days/3 months. a–e Analyses were performed in the mITT analysis set using the descriptive model. p values were generated by the Wilcoxon signed-rank test and are pointed under the respective graphs. Data are shown as percentage mean with SD. n number of patients with available data for the respective time point; CD, Crohn's disease; TWPI, total work productivity impairment; IFX, infliximab; BL, baseline; mITT, modified intention to treat.